A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.
Journal
Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R
Informations de publication
Date de publication:
16 01 2021
16 01 2021
Historique:
received:
18
09
2020
revised:
02
11
2020
accepted:
10
11
2020
entrez:
17
1
2021
pubmed:
18
1
2021
medline:
23
2
2021
Statut:
ppublish
Résumé
Management of type 1 diabetes is challenging. We compared outcomes using a commercially available hybrid closed-loop system versus a new investigational system with features potentially useful for adolescents and young adults with type 1 diabetes. In this multinational, randomised, crossover trial (Fuzzy Logic Automated Insulin Regulation [FLAIR]), individuals aged 14-29 years old, with a clinical diagnosis of type 1 diabetes with a duration of at least 1 year, using either an insulin pump or multiple daily insulin injections, and glycated haemoglobin (HbA Between June 3 and Aug 22, 2019, 113 individuals were enrolled into the trial. Mean age was 19 years (SD 4) and 70 (62%) of 113 participants were female. Mean proportion of time with daytime glucose levels above 180 mg/dL (>10·0 mmol/L) was 42% (SD 13) at baseline, 37% (9) during use of the 670G system, and 34% (9) during use of the advanced hybrid closed-loop system (mean difference [advanced hybrid closed-loop system minus 670G system] -3·00% [95% CI -3·97 to -2·04]; p<0·0001). Mean 24-h proportion of time with glucose levels below 54 mg/dL (<3·0 mmol/L) was 0·46% (SD 0·42) at baseline, 0·50% (0·35) during use of the 670G system, and 0·46% (0·33) during use of the advanced hybrid closed-loop system (mean difference [advanced hybrid closed-loop system minus 670G system] -0·06% [95% CI -0·11 to -0·02]; p<0·0001 for non-inferiority). One severe hypoglycaemic event occurred in the advanced hybrid closed-loop system group, determined to be unrelated to study treatment, and none occurred in the 670G group. Hyperglycaemia was reduced without increasing hypoglycaemia in adolescents and young adults with type 1 diabetes using the investigational advanced hybrid closed-loop system compared with the commercially available MiniMed 670G system. Testing an advanced hybrid closed-loop system in populations that are underserved due to socioeconomic factors and testing during pregnancy and in individuals with impaired awareness of hypoglycaemia would advance the effective use of this technology FUNDING: National Institute of Diabetes and Digestive and Kidney Diseases.
Sections du résumé
BACKGROUND
Management of type 1 diabetes is challenging. We compared outcomes using a commercially available hybrid closed-loop system versus a new investigational system with features potentially useful for adolescents and young adults with type 1 diabetes.
METHODS
In this multinational, randomised, crossover trial (Fuzzy Logic Automated Insulin Regulation [FLAIR]), individuals aged 14-29 years old, with a clinical diagnosis of type 1 diabetes with a duration of at least 1 year, using either an insulin pump or multiple daily insulin injections, and glycated haemoglobin (HbA
FINDINGS
Between June 3 and Aug 22, 2019, 113 individuals were enrolled into the trial. Mean age was 19 years (SD 4) and 70 (62%) of 113 participants were female. Mean proportion of time with daytime glucose levels above 180 mg/dL (>10·0 mmol/L) was 42% (SD 13) at baseline, 37% (9) during use of the 670G system, and 34% (9) during use of the advanced hybrid closed-loop system (mean difference [advanced hybrid closed-loop system minus 670G system] -3·00% [95% CI -3·97 to -2·04]; p<0·0001). Mean 24-h proportion of time with glucose levels below 54 mg/dL (<3·0 mmol/L) was 0·46% (SD 0·42) at baseline, 0·50% (0·35) during use of the 670G system, and 0·46% (0·33) during use of the advanced hybrid closed-loop system (mean difference [advanced hybrid closed-loop system minus 670G system] -0·06% [95% CI -0·11 to -0·02]; p<0·0001 for non-inferiority). One severe hypoglycaemic event occurred in the advanced hybrid closed-loop system group, determined to be unrelated to study treatment, and none occurred in the 670G group.
INTERPRETATION
Hyperglycaemia was reduced without increasing hypoglycaemia in adolescents and young adults with type 1 diabetes using the investigational advanced hybrid closed-loop system compared with the commercially available MiniMed 670G system. Testing an advanced hybrid closed-loop system in populations that are underserved due to socioeconomic factors and testing during pregnancy and in individuals with impaired awareness of hypoglycaemia would advance the effective use of this technology FUNDING: National Institute of Diabetes and Digestive and Kidney Diseases.
Identifiants
pubmed: 33453783
pii: S0140-6736(20)32514-9
doi: 10.1016/S0140-6736(20)32514-9
pmc: PMC9194961
mid: NIHMS1672134
pii:
doi:
Substances chimiques
Insulin
0
Banques de données
ClinicalTrials.gov
['NCT03040414']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
208-219Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK036836
Pays : United States
Organisme : NIDDK NIH HHS
ID : UC4 DK108611
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
N Engl J Med. 1993 Sep 30;329(14):977-86
pubmed: 8366922
N Engl J Med. 2019 Oct 31;381(18):1707-1717
pubmed: 31618560
Diabetes Care. 2019 Mar;42(3):400-405
pubmed: 30352896
Diabetes Care. 2021 Apr;44(4):969-975
pubmed: 33579715
N Engl J Med. 2020 Aug 27;383(9):836-845
pubmed: 32846062
Lancet. 2018 Oct 13;392(10155):1321-1329
pubmed: 30292578
Diabetes Technol Ther. 2015 Sep;17(9):657-63
pubmed: 25923812
Diabetes Obes Metab. 2020 Apr;22(4):688-693
pubmed: 31709736
Lancet. 2019 Oct 5;394(10205):1265-1273
pubmed: 31533908
Diabetes Care. 2019 Aug;42(8):1593-1603
pubmed: 31177185
Diabetes Care. 2019 Dec;42(12):2190-2196
pubmed: 31548247
Diabetes Obes Metab. 2020 Apr;22(4):583-589
pubmed: 31789447
Pediatr Diabetes. 2020 Mar;21(2):319-327
pubmed: 31885123
Diabetes Care. 2014 Nov;37(11):3025-32
pubmed: 25078901
N Engl J Med. 2013 Feb 28;368(9):824-33
pubmed: 23445093
Curr Diab Rep. 2019 Jun 27;19(8):50
pubmed: 31250124
Diabetes Technol Ther. 2017 Mar;19(3):155-163
pubmed: 28134564
JAMA. 2016 Oct 4;316(13):1407-1408
pubmed: 27629148
Diabetes Care. 2010 May;33(5):1072-6
pubmed: 20150292
Pediatr Diabetes. 2020 Mar;21(2):310-318
pubmed: 31837064